Celltrion’s biosimilar Remsima gets EU green light

Published: 2013-07-02 07:00:00

Updated: 2013-07-02 07:00:00

Biopharmaceutical company Celltrion said Monday its biosimilar monoclonal antibody Remsima has won approval by the European Medicines Agency, setting out a clearer path for the local drugmaker to export the drug to 30 countries in Europe.

Remsima is a biosimilar version of U.S. Merck’s Remicade, a globally renowned medication for rheumatoid arthritis. Biosimilars are effectively copies of in...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.